Portal Diabetes’ insulin pump receives FDA breakthrough device designation 

The designation supports priority engagement with the FDA as Portal Diabetes advances clinical trials and regulatory submissions.

Portal Diabetes has received the US Food and Drug Administration (FDA) breakthrough device designation for its implantable insulin pump system, known as the Portal Pump.

It has also initiated a Phase I study of its temperature-stable insulin, referred to as Portal Insulin.

The company aims to provide a functional solution for people with type 1 diabetes (T1D) by combining an implantable pump delivering insulin into the abdomen, continuous glucose monitoring (CGM) technology, and concentrated insulin to create a fully automated insulin delivery system.

Free Sample

Download sample pages of selected reports

Explore a selection of report samples we have handpicked for you. Get a preview of the insights inside. Download your free copy today.

The designation is expected to support priority engagement with the FDA as Portal Diabetes moves ahead with clinical trials and regulatory submissions.

This designation also makes the Portal Pump eligible for transitional coverage for emerging technologies (TCET) pathway, which can accelerate Medicare coverage once approved as a breakthrough device.

Under an investigational new drug (IND) application, the initial two patients have been administered Portal Insulin through injection into the intraperitoneal space at a clinical centre in San Diego, California, US. This step marks an important milestone in developing the Portal Pump Combination System.

Clinical trials of the full combination system are expected to commence around the fourth quarter of 2027.

The Portal Pump is not authorised for sale or investigational use in the US at present. Portal Insulin remains an IND and is not commercially available in the country.

Portal Diabetes CEO Stacy Chambliss said: “We believe patients will achieve much better glycaemic control for a dramatically reduced mental burden with the Portal Pump.

“Step by step, we are working diligently to bring long-awaited technology to patients living with T1D. Today, we celebrate the first clinical injections of Portal Insulin, a momentous occasion for the combination system.”

Unlock up to 35% savings on GlobalData reports

Use the code at checkout in the report store

  • 20% OFF

    Buy 2 reports

    Use code:

    Bundle20

  • 25% OFF

    Buy 3 reports

    Use code:

    Bundle25

  • 30% OFF

    Buy 4 reports

    Use code:

    Bundle30

  • 35% OFF

    Buy 5+ reports

    Use code:

    Bundle35

Valid on all reports priced $995 and above. Cannot be combined with other offers.

Still deciding what will work best for your business?

Ask our experts for help.

Enquire before buying